
NOTES TO EDITORS

Please be advised

This release is from Boehringer Ingelheim Corporate Headquarters in Germany. Please be aware that there may be national differences between countries regarding specific medical information, including licensed uses. Please take account of this when referring to the information provided in this document. This press release is not intended for distribution within the U.S.A.

About telmisartan (Micardis[®]/Kinzal[®]/Pritor[®])

Telmisartan is a modern member of the Angiotensin II Receptor Blocker (ARB) class and is being investigated in the most ambitious and far-reaching research programme conducted with an ARB. In the clinical trial programmes ONTARGET[®], PROTECTION[®] and PRoFESS[®], over 58,000 patients have been enrolled to investigate the cardiovascular protective effects of telmisartan (for more information please visit www.news-landmarktrials.com).

Telmisartan was discovered and developed by Boehringer Ingelheim. Under the trademarks MICARDIS[®] and MICARDISPLUS[®] (combination with hydrochlorothiazide) the company markets telmisartan in 84 countries around the world, including the USA, Japan and European countries. Telmisartan is marketed in cooperation with Astellas Pharma Inc. in Japan, Bayer HealthCare in Europe and GlaxoSmithKline in selected markets.

Astellas Pharma Inc. co-promotes telmisartan under the trademark MICARDIS[®], Bayer HealthCare promotes telmisartan under the brand names Kinzalmono[®], Kinzalkomb[®] (combination with hydrochlorothiazide), and Pritor[®] and PritorPlus[®] (combination with hydrochlorothiazide) in markets across Europe. Pritor[®] and PritorPlus[®] is also marketed by GlaxoSmithKline in selected markets.

The sponsor of the ONTARGET[®] Trial Programme is Boehringer Ingelheim; co-funders in selected countries are Bayer HealthCare and GlaxoSmithKline.

Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

For more information please visit www.boehringer-ingelheim.com

Related links:

www.news-ontarget.com

www.ontarget-telmisartan.com

www.micardis.com

Contact

Corporate Division Communications

Boehringer Ingelheim GmbH

55216 Ingelheim/Germany

Phone: + 49 - 6132 - 77 97296, 77- 8271

Fax: + 49 - 6132 - 72 6601

E-mail: press@boehringer-ingelheim.com

References

1. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. *Lancet* Published online 31 August 2008.
2. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med* 2000; **342**:145-53.
3. The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Eng J Med* 2008; **358**(15):1547-59.
4. Israili ZH, Hall WD. Cough and angioedema associated with angiotensin-coverting enzyme inhibitor therapy. A review of the literature and pathophysiology. *Ann Intern Med* 1992; **117**(3):234-42.

5. Matchar DB, *et al.* Systematic Review: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. *Ann Intern Med* 2008; **148**:16-29.
6. Macaulay TE, Dunn SP. Cross-reactivity of ACE-inhibitor-induced angioedema with ARBs. *US Pharmacist* 2007; **32** (2).
7. World Health Organization, Fact Sheet 317: Cardiovascular Diseases February 2007.
<http://www.who.int/mediacentre/factsheets/fs317/en/index.html> (Accessed August 2008)
8. Murray CJL, Lopez AD. eds. The Global Burden of Disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge; Harvard University Press 2001.
9. Primary Prevention of Ischemic Stroke. A Guideline from the American Heart Association/American Stroke Association Stroke Council. *Stroke* 2006; **37**:1583-1633.